The present invention provides a multispecific antigen binding molecule comprising a first antigen binding domain having RNF43 binding activity and a second antigen binding domain having T cell receptor complex binding activity, and such a multispecific antigen binding molecule. Provide usage etc. The inventors of the present invention include a novel multiplex that includes a first antigen-binding domain having RNF43 binding activity and a second antigen-binding domain having T cell receptor complex-binding activity, excellent cytotoxicity and high stability. A specific antigen binding molecule was discovered. Since the molecule of the present invention exhibits strong cytotoxicity to cells and tissues expressing RNF43, a novel pharmaceutical composition containing a multispecific antigen-binding molecule for treating or preventing various cancers. It is possible to manufacture things.本発明は、RNF43結合活性を有する第1抗原結合ドメインとT細胞受容体複合体結合活性を有する第2抗原結合ドメインとを含む多重特異性抗原結合分子、そのような多重特異性抗原結合分子の使用等を提供する。本発明者らは、RNF43結合活性を有する第1抗原結合ドメインとT細胞受容体複合体結合活性を有する第2抗原結合ドメインとを含む、細胞傷害性が優れかつ安定性が高い、新規な多重特異性抗原結合分子を発見した。本発明の分子は、RNF43を発現する細胞および組織に対して強力な細胞傷害性を示すため、様々ながんを治療または予防するための、多重特異性抗原結合分子を含む新規な薬学的組成物を製造することが可能である。
